top of page

NEWS & PUBLICATIONS

07/24/2025

U.K. MHRA Awards Tern Therapeutics Innovation Passport for TTX-381 to Accelerate Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease

06/03/2025

Tern Therapeutics Receives US FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease

04/08/2025

Tern Therapeutics Receives US FDA Fast Track Designation for TTX-381 Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease

02/27/2025

Tern Therapeutics Issues CLN2 Batten Community Letter, February 2025

02/10/2025

Tern Therapeutics Advances Pipeline and Presents Positive Clinical Data for TTX-381 and TTX-181 Gene Therapies for CLN2 Batten Disease at 21st Annual WORLDSymposium

08/27/2024

Tern Therapeutics Launches with $15 Million Financing and Pipeline in CLN2 Batten Disease

bottom of page